22 June 2018
Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV) requests an immediate trading halt with respect to its ordinary shares listed on the ASX.
Recent Posts
CLINUVEL Vitiligo Communiqué
19 December 2018 As a depigmentation disorder hypomelanosis vitiligo is the most...
Read More
CUV103 Singaporean Phase II vitiligo study results
19 December 2018 SUMMARY Phase II study in vitiligo, a treatment-resistant disease1...
Read More